Compare DGICB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | PHAR |
|---|---|---|
| Founded | 1986 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.2M | 1.0B |
| IPO Year | 1995 | 2020 |
| Metric | DGICB | PHAR |
|---|---|---|
| Price | $24.49 | $12.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | 10.0K | ★ 15.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $978,014,322.00 | N/A |
| Revenue This Year | $2.26 | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $8.06 | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.02 | $9.62 |
| 52 Week High | $29.99 | $21.34 |
| Indicator | DGICB | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 51.77 |
| Support Level | $15.24 | $12.08 |
| Resistance Level | $24.20 | $13.61 |
| Average True Range (ATR) | 1.05 | 0.68 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 73.98 | 71.08 |
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.